Rating of The Day: Joh. Berenberg Gossler & Co. KG Analyst Reaffirmed EUR 101.00 Price Target on Merck (ETR:MRK) stock, While Reiterating “Hold” Rating

November 23, 2016 - By Louis Casey

Rating of The Day: Joh. Berenberg Gossler & Co. KG Analyst Reaffirmed EUR 101.00 Price Target on Merck (ETR:MRK) stock, While Reiterating

Merck (ETR:MRK) Rating

Merck (ETR:MRK) had its stock rating noted as “Hold” by analysts at Joh. Berenberg Gossler & Co. KG. Joh. Berenberg Gossler & Co. KG currently has a EUR 101.00 target on the 12.02 billion EUR market cap company or 8.38% upside potential. This was shown in an analyst report on Wednesday morning.

Merck KGaA (ETR:MRK) Ratings Coverage

Out of 22 analysts covering Merck (ETR:MRK), 11 rate it a “Buy”, 2 “Sell”, while 9 “Hold”. This means 50% are positive. €115 is the highest target while €75 is the lowest. The €101.31 average target is 8.89% above today’s (€93.04) stock price. Merck has been the topic of 115 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Societe Generale given on Thursday, November 17. Baader Wertpapierhandelsbank maintained it with “Hold” rating and €96 target price in Monday, January 4 report. The stock of Merck KGaA (ETR:MRK) has “Buy” rating given on Thursday, August 6 by Commerzbank. The firm has “Outperform” rating given on Thursday, May 19 by BNP Paribas. Landesbank upgraded it to “Buy” rating and €112 target price in Saturday, August 6 report. The firm earned “Buy” rating on Wednesday, December 9 by Citigroup. The firm has “Buy” rating given on Wednesday, November 16 by Landesbank. The stock has “Neutral” rating given by JP Morgan on Friday, July 22. Equinet upgraded the shares of MRK in a report on Tuesday, July 19 to “Accumulate” rating. The stock has “Neutral” rating given by Equinet on Friday, April 22.

About 141,532 shares traded hands. Merck KGaA (ETR:MRK) has risen 9.01% since April 21, 2016 and is uptrending. It has outperformed by 3.68% the S&P500.

Insitutional Activity: The institutional sentiment decreased to 1.05 in 2016 Q2. Its down 0.02, from 1.07 in 2016Q1. The ratio dived, as 51 funds sold all Merck KGaA shares owned while 583 reduced positions. 96 funds bought stakes while 583 increased positions. They now own 1.97 billion shares or 0.55% less from 1.98 billion shares in 2016Q1.

Moreover, Mesirow Investment Mngmt has 0.06% invested in Merck KGaA (ETR:MRK) for 17,693 shares. Mount Vernon Incorporated Md accumulated 3,570 shares or 0.44% of the stock. Winton Capital Gp reported 136,982 shares or 0.13% of all its holdings. Private Gru accumulated 372,463 shares or 1.41% of the stock. Stock Yards Bank & Tru accumulated 0.43% or 56,405 shares. Moreover, Aimz Invest Advsr Ltd Co has 0.59% invested in Merck KGaA (ETR:MRK) for 11,092 shares. Bluecrest holds 0.01% of its portfolio in Merck KGaA (ETR:MRK) for 4,930 shares. South State Corp reported 77,301 shares or 0.67% of all its holdings. Buckhead Mgmt Lc last reported 10,992 shares in the company. Marble Harbor Inv Counsel Ltd Liability Com holds 0.87% of its portfolio in Merck KGaA (ETR:MRK) for 61,054 shares. Archford Cap Strategies Limited Company accumulated 0.13% or 4,327 shares. Busey Tru owns 83,818 shares or 0.62% of their US portfolio. High Point Fincl Bank And has invested 0.06% of its portfolio in Merck KGaA (ETR:MRK). Hourglass Ltd Llc last reported 15,058 shares in the company. Lucas Mngmt owns 8,455 shares or 0.34% of their US portfolio.

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The company has a market cap of 12.02 billion EUR. The Firm diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. It has a 27.31 P/E ratio. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.

According to Zacks Investment Research, “Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.”

MRK Company Profile

Merck & Co., Inc., incorporated on 1970, is a global healthcare company. The Firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. The Firm has activities in Pharmaceutical, Animal Health, Alliances and Healthcare Services divisions. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

More notable recent Merck KGaA (ETR:MRK) news were published by: Marketwatch.com which released: “Merck KGaA net income rises 25.5%” on November 15, 2016, also Businesswire.com with their article: “QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck …” published on November 22, 2016, Wsj.com published: “Germany’s Merck Builds Up Non-Drug Businesses” on August 25, 2016. More interesting news about Merck KGaA (ETR:MRK) were released by: Wsj.com and their article: “Merck KGaA Lifts Profit Outlook as Sales Jump” published on August 04, 2016 as well as Fiercebiotech.com‘s news article titled: “Merck KGaA returns PhII multiple sclerosis drug to Apitope” with publication date: October 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>